2017年 · 第26卷第06期

Trihydroxyisoflavone (Genistein) is the main component of soybean isoflavone, which belongs to polyphenol compounds, and has biological effects such as inhibiting the occurrence of cardiovascular diseases and antitumor. Foreign studies have shown that Genistein combined with radiation can enhance the radiosensitivity of tumors, such as liver cancer, esophageal cancer, prostate cancer and cervical cancer^[1,2,3,4]。 However, the effect of Genistein combined with radiation on radiosensitivity of glioma has not been reported yet. In this experiment, Genistein combined with radiation was applied to U251 cells to observe its effect on the proliferation and apoptosis of U251 cells, and the effect of Genistein on the radiosensitivity of U251 cells was studied, which provided a reliable basis for the application of Genistein in the treatment of glioma, in order to improve the radiotherapy effect of glioma.

HERG₁Also known as KCNH₂or KvlLl, is a member of the family of voltage-gated potassium ion channels for fast delay rectification^[1], there is growing evidence that HERG₁Highly expressed in a variety of tumor cells^[2,3,4,5,6]It is closely related to tumor cell proliferation, apoptosis, differentiation and invasion, but is not expressed in corresponding normal cells^[4,5,6,7]。 The expression of miR-96 is down-regulated in pancreatic cancer tissues, and its target gene HERG₁It can affect cell proliferation, apoptosis, invasion and migration by regulating related signaling pathways. Relevant studies showed that the proliferation, colony formation, migration and invasion of pancreatic cancer cells PANC-1 with miR-96 overexpression were significantly weakened, and apoptosis increased^[8]。 In this study, PANC-1 cells were studied to study the effect of miR-96 on its radiosensitivity, in order to provide new ideas for the clinical treatment of pancreatic cancer.

With the development of science and technology, high-precision tumor radiotherapy has been widely carried out. IGRT technology enables tumor patients to obtain the image information of the projection area in advance before radiotherapy, correct the position error, and improve the accuracy of dose administration. As one of the world's largest suppliers of medical linear accelerators, Varian adopts OBI and PortalVision as its IGRT solutions, and has now launched several models equipped with OBI and PortalVision, such as IX, Trilogy, etc. At present, the author's unit has two sets equipped with OBI system^[1]Varian Medical Linear Accelerator is in service, and it has encountered many problems in daily use. Now I will summarize some experience in repair and maintenance, and share it with my colleagues, hoping to be helpful.

On May 4-6, 2017, the 2nd National Radiotherapy Target Area Delineation Class in 2017, sponsored by the Radiation Oncology Therapy Branch of Beijing Medical Association and hosted by Peking University Third Hospital and Peking University International Hospital, was successfully held in the multifunctional hall of Beijing Wanshou Hotel. Jin Dapeng, president of Beijing Medical Association, attended the opening ceremony and delivered a speech at the conference. Professor Wang Junjie, chairman of Radiotherapy Branch of Beijing Medical Association and director of Radiotherapy Department of Peking University Third Hospital and Peking University International Hospital, presided over it. Nearly 500 radiotherapy scholars from all over the country attended, and there were full seats on the spot. The number of clicks on the live webcast video reached more than 24,000 times, and the students interacted enthusiastically on the spot.

The 12th Pan-Pearl River Regional Radiation Oncology Academic Conference and the 2nd Hainan Anti-Cancer Association Tumor Radiotherapy Academic Conference jointly sponsored by Pan-Pearl River Regional Cancer Radiotherapy Collaborative Group (PPRA-RTOG), Hainan Anti-Cancer Association Tumor Radiotherapy Professional Committee, Hainan Provincial People's Hospital and China Anti-Cancer Association Tumor Radiotherapy Professional Committee were successfully held in Haikou City, Hainan Province on April 20-23, 2017. The theme of this year's 12th academic conference is "Developing Regional Advantages and Promoting Discipline Development". Professor Lang Jinyi, Chairman of Radiation Oncology Branch of Chinese Medical Association, Professor Li Yongmei, Chairman of Clinical Oncology Department of the University of Hong Kong, and Professor Wei Xiong of MD Anderson Cancer Center in the United States respectively reported on the challenges and thinking of radiation therapy in the era of artificial intelligence , concurrent-adjuvant chemo-radiotherapy for locoregionally advanced nasopharyngeal cancer 10-year efficacy and late toxicities And the thinking of modern radiotherapy technology on improving radiotherapy quality of life and reducing radiotherapy injury.